Software Targets Wasted Healthcare Spending for Hospital Acquired Conditions Costing Over $22 Billion Annually
DAYTONA BEACH, Fla., July 30, 2012 /PRNewswire/ -- Quture International, Inc. (OTCQB: TCLN) and its operations subsidiary Quture, Inc. ("Quture") today announces the successful completion of electronic clinical data capture at Niagara Falls Memorial Medical Center (NFMMC), Niagara Falls, New York, for the interdisciplinary QualOptima product. The QualOptima analytics system will determine return on investment (ROI) for commercial sales to hospitals and other potential customers. ROI analytics are scheduled for completion on August 31.
The partnership between Quture and InterSystems Corporation (Cambridge, MA) and ExcelCare, Inc. (Ligonier, PA) will complete the return on investment analysis for commercial sales, supplementing physician performance analytics at the University of Miami. Nursing data from Quture's strategic alliance with ExcelCare exponentially enhances the performance measurement value of the product. The benefit of QualOptima to improve care while reducing costs targets the prevention of Hospital Acquired Conditions (HAC). Overall, the costs to treat patients who experience these preventable conditions were over $22 billion in 2007 alone. CMS and Medicare are aggressively withholding reimbursement for treatment of patients who acquire these conditions in hospitals, totaling millions of dollars annually and growing at the rate of 20% annually.
NFMMC is a long-established customer of ExcelCare providing an extraordinary clinical setting to transform manual data collection to electronic data capture on the InterSystems platform. The NFMCC project has implemented an evidence-based optimal clinical process for on prevention of catheter-acquired urinary tract infections (CAUTI) in the intensive care unit. This clinical condition was selected as an example of Hospital Acquired Conditions (HAC), which is one of several federal initiatives of the Centers for Medicare and Medical Services (CMS) targeted for significant payment reductions. The ROI analysis is focused on payment initiatives, such as Accountable Care Organizations (ACO) as well as value-based purchasing.
Landon Feazell, Chairman and CEO of Quture, in collaboration with Dr. Judith Daugherty, President & CEO of ExcelCare said: "We are committed to integrating nursing and physician clinical performance for measurement and analytics. For hospitals to be competitive, profitable, and meet federal mandates in the immediate future, manual and paper-based patient care and nursing-sensitive quality processes and data collection must rapidly transition to electronic systems."
"Upon completion of the ROI analysis, this is yet another significant milestone for the commercial release and sales of our QualOptima product. Our strategy is to introduce transformative tools that improve care and reduce costs as innovators in the private enterprise sector," said Feazell.
ABOUT QUTURE INTERNATIONAL, INC. (www.quture.com)
Quture International, Inc. is an emerging growth company positioned to become the leading clinical knowledge company in the world. The core competence of Quture is clinical performance enhancement to achieve optimal patient outcomes. Quture's brand is centered on the value proposition of trust, transparency and independence. As the free enterprise solution to improving health and health care while reducing costs, Quture is comprised of a subsidiaries in North America and Europe for the operations of its software technology solutions, plans for a "beyond data" consulting and knowledge applications company, as well as plans for a personalized, proactive, and predictive medicine company with a virtual community of members. These subsidiaries will all be affiliated with the Qx Medical Exchange, which the Company intends to become the largest medical and health exchange in the world. Quture International is a Nevada corporation currently trading under the symbol TCLN.
This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. There is no assurance that a definitive agreement will be completed.
For Further Information Contact:
Constellation Asset Advisors, Inc.
Jens Dalsgaard
President
+1 (415) 524-8500
Contact: Mele Telitz, Director of Communications
303-204-4486; [email protected]
SOURCE Quture International, Inc.